Clinical Trials Browser

Active not recruiting × Lymphoma, B-Cell, Marginal Zone × ibrutinib × Clear all

Lymphoma, B-Cell, Marginal Zone

NCT03479268 2025-11-26

Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Prolymphocytic, B-Cell

NCT01955499 2025-11-10

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Phase 1 Active not recruiting

39 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01479842 2025-10-15

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

Phase 1 Active not recruiting

48 enrolled

Lymphoid

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04212013 2025-07-23

A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma

Phase 3 Active not recruiting

23 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

Clinical Trials

MALIBU

Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma